EP
AGIO icon

Essential Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Essential Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.7K Buy
557
+552
+11,040% +$16.7K 0.01% 890
2026
Q1 		$169 Hold
5
– – ﹤0.01% 2639
2025
Q4 		$136 Sell
5
-110
-96% -$3.86K ﹤0.01% 2508
2025
Q3 		$4.62K Hold
115
– – ﹤0.01% 1454
2025
Q2 		$3.83K Buy
+115
New +$3.49K ﹤0.01% 1132

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Essential Partners's AGIO Position: Q2 2026 in Review

Essential Partners increased its Agios Pharmaceuticals (AGIO) stake by 11,040% in Q2 2026, buying an estimated $16.7K and bringing the position to 557 shares worth $20.7K. The position accounts for 0.01% of the portfolio, ranked #890.

Essential Partners first reported a position in AGIO in Q2 2025 and has held it in 5 quarters since. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Essential Partners held 557 shares of Agios Pharmaceuticals worth $20.7K as of Q2 2026.
  • Essential Partners bought 552 Agios Pharmaceuticals shares in Q2 2026, an estimated $16.7K.
  • Agios Pharmaceuticals made up 0.01% of Essential Partners's portfolio in Q2 2026, its #890 holding.
  • Essential Partners first reported a position in Agios Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.